Brandon Schnittker

About Brandon Schnittker

Brandon Schnittker, age 41, is Division President, GYN Surgical Solutions at Hologic (HOLX). He joined Hologic in May 2022 as Vice President of Surgical Sales and was promoted to Division President effective January 2024. He holds a BS from The Ohio State University and an MBA from UNC Kenan-Flagler; prior to Hologic he spent 16 years at Stryker, including serving as Director of Marketing for Stryker ENT from 2016 to early 2022 . During fiscal 2024, GYN Surgical revenue grew 6.1% in constant currency to $641.3M, led by MyoSure, Fluent, and adoption in the laparoscopic portfolio (Acessa, Bolder), with continued momentum in Q4 FY25 as Surgical revenue rose 10.2% year-over-year to $172.5M; company performance frameworks emphasize adjusted revenue/EPS, adjusted ROIC, adjusted FCF, and relative TSR in pay-for-performance alignment .

Past Roles

External Roles

Fixed Compensation

• Specific base salary, target bonus %, and actual bonus paid for Mr. Schnittker are not disclosed (he is not a named executive officer in the proxy). Hologic’s executive compensation programs include fixed base salary and cash short-term incentives (STIP) determined by role and performance .

Performance Compensation

• Vesting schedules: RSUs vest annually over three years; stock options vest annually over four years; PSUs vest after three years based on performance (Adjusted FCF, Adjusted ROIC, Relative TSR) .

Equity Ownership & Alignment

• Beneficial ownership, pledged shares, and vested/unvested breakdown for Mr. Schnittker are not disclosed in the proxy’s ownership tables (table lists directors and NEOs) .

Employment Terms

• Employment agreement terms, severance, and change-of-control specifics for Mr. Schnittker are not disclosed. Company-wide frameworks include double-trigger change-of-control provisions and severance/change-of-control agreements for certain executive officers (e.g., CEO and NEOs), capping severance under new agreements at ≤2.99x salary+bonus; change-of-control agreements provide 2.99x cash severance and equity vesting for specified terminations within three years of a change-of-control .
• In the announced transaction to be acquired by funds managed by Blackstone and TPG, company equity awards would be treated at closing: options vest in full; certain options convert to cash and/or contingent value rights (CVRs); RSUs convert to merger consideration, with performance RSUs deemed achieved at the greater of target or actual measured through the latest practicable date prior to closing (per merger agreement terms). Individual treatment depends on award type; executive-specific outcomes are not disclosed .

Performance & Track Record

• Company context: FY2024 total revenue was ~$4.03B, with non-GAAP operating margin of ~30% and non-GAAP gross margin ~61% .

Compensation Structure Analysis

• Strong pay-for-performance design: Short-term incentives based on adjusted revenue and adjusted EPS (weighted 60/40); long-term incentives balanced across adjusted FCF (50%), adjusted ROIC (25%), and relative TSR (25%) with three-year performance periods and PSU payout caps for negative TSR .
• Governance safeguards: No tax gross-ups, prohibition on hedging/pledging, clawback policy aligned to SEC/Nasdaq rules, independent compensation consultant, annual risk assessments .

Say-on-Pay & Shareholder Feedback

• Say-on-Pay approvals increased to 79% at the 2024 Annual Meeting; management conducted outreach to top institutional investors (~55% of shares), with feedback supportive of continuity in program design and performance-based alignment .

Expertise & Qualifications

• Education: BS (Ohio State); MBA (UNC Kenan-Flagler) .
• Industry experience: 16 years at Stryker in commercial/marketing leadership; medtech operating and portfolio execution expertise .
• Hologic roles: Commercial and divisional leadership in GYN Surgical (since 2022; Division President since 2024) .

Risk Indicators & Red Flags

• No individual legal proceedings, SEC investigations, hedging/pledging or related party transactions disclosed for Mr. Schnittker in proxy or 8-K filings. Company-wide policies prohibit hedging/pledging and include clawbacks; related party transactions reviewed by the Audit & Finance Committee .

Investment Implications

• Execution leverage: GYN Surgical demonstrated consistent growth through FY2024 and accelerated in Q4 FY25; continued adoption of core products and integration of Gynesonics broaden the addressable portfolio—supportive of divisional performance under Schnittker’s leadership .
• Incentive alignment: Although individual pay details are not disclosed for Mr. Schnittker, Hologic’s executive compensation framework ties payouts to adjusted revenue/EPS and longer-term FCF/ROIC/TSR, with robust governance (ownership guidelines, clawbacks, no hedging) that should align divisional decision-making with shareholder value creation .
• Change-of-control dynamics: Pending acquisition terms indicate accelerated vesting/treatment for equity awards at closing (award-type dependent), with CVRs linked to Breast Health revenue milestones; while divisional economics for GYN Surgical are not directly tied to CVR metrics, retention and equity conversion outcomes could influence executive continuity and focus through close .

Note: Specific compensation, equity holdings, and insider trading activity for Mr. Schnittker are not disclosed in the proxy and were not found in the filings searched; analysis relies on company-wide frameworks and divisional performance disclosures .